Non-covid mRNA Vaccine and Therapeutics Market
完整報告名稱與涵蓋範圍
Non-covid mRNA Vaccine and Therapeutics Market Size, Share & Trends Analysis Distribution by Product Type (mRNA Therapeutic, mRNA Vaccines), Therapeutic Area (Infectious Diseases, Oncological Disorders, Other Disorders), Route of Administration (Intravenous, Intramuscular, Intranasal, Others) and Segment Forecasts, 2024-2031
報告摘要
The worldwide Non-covid mRNA Vaccine and Therapeutics Market stood at USD 370 Mn in 2024, and is poised to reach USD 1,684.80 Mn by 2031, recording a CAGR of 24.20% from 2024 through 2031.
Non-covid mRNA Vaccine and Therapeutics covers reshaping how healthcare entities approach this space.
The market's upward path is bolstered by mounting healthcare spending, technological evolution, and the mounting focus on personalized and precision-based approaches in healthcare.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold pronounced shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Non-covid mRNA Vaccine and Therapeutics Market Snapshot
Chapter 4. Global Non-covid mRNA Vaccine and Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Non-covid mRNA Vaccine and Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Non-covid mRNA Vaccine and Therapeutics Industry Trends
Chapter 5. Non-covid mRNA Vaccine and Therapeutics Market Segmentation 1: By Product Type, Estimates & Trend Analysis
5.1. Market Share by Product Type, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2031 for the following Product Type:
5.2.1. mRNA Therapeutic
5.2.2. mRNA Vaccines
Chapter 6. Non-covid mRNA Vaccine and Therapeutics Market Segmentation 2: By Therapeutic Area, Estimates & Trend Analysis
6.1. Market Share by Therapeutic Area, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2031 for the following Therapeutic Areas:
6.2.1. Infectious Diseases
6.2.1.1. Influenza
6.2.1.2. Respiratory Syncytial Virus (RSV)
6.2.1.3. Cytomegalovirus
6.2.1.4. Others
6.2.2. Oncological Disorders
6.2.3. Other Disorders
Chapter 7. Non-covid mRNA Vaccine and Therapeutics Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2031 for the following Route of Administration:
7.2.1. Intravenous
7.2.2. Intramuscular
7.2.3. Intranasal
7.2.4. Others
Chapter 8. Non-covid mRNA Vaccine and Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Non-covid mRNA Vaccine and Therapeutics Market, Regional Snapshot 2024 & 2031
8.2. North America
8.2.1. North America Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
8.2.3. North America Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2024-2031
8.2.4. North America Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
8.3. Europe
8.3.1. Europe Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
8.3.3. Europe Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2024-2031
8.3.4. Europe Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
8.4. Asia Pacific
8.4.1. Asia Pacific Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
8.4.3. Asia Pacific Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2024-2031
8.4.4. Asia Pacific Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
8.5. Latin America
8.5.1. Latin America Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
8.5.3. Latin America Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2024-2031
8.5.4. Latin America Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
8.6. Middle East & Africa
8.6.1. Middle East & Africa Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
8.6.3. Middle East & Africa Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2024-2031
8.6.4. Middle East & Africa Non-covid mRNA Vaccine and Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. CureVac
9.2.1.1.1. Business Overview
9.2.1.1.2. Key Product/Service Offerings
9.2.1.1.3. Financial Performance
9.2.1.1.4. Geographical Presence
9.2.1.1.5. Recent Developments with Business Strategy
9.2.2. Anima Biotech
9.2.3. Arcturus Therapeutics
9.2.4. BioNTech (Pfizer)
9.2.5. eFFECTOR Therapeutics, Inc.
9.2.6. eTheRNA
9.2.7. Ethris (AstraZeneca)
9.2.8. H3 Biomedicine Inc. (Eisai Inc.)
9.2.9. In-Cell-Art
9.2.10. Ionis Pharmaceuticals, Inc.
9.2.11. Kernal Biologics
9.2.12. Moderna
9.2.13. RNAimmune (Sirnaomics)
9.2.14. Silence Therapeutics
9.2.15. Skyhawk Therapeutics, Inc.
9.2.16. Stemirna Therapeutics Co., Ltd.
9.2.17. Tiba Biotechnology
9.2.18. Translate Bio Sanofi)
9.2.19. Ziphius Therapeutics NV
9.2.20. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們